DIABETES AND CRITICAL LIMB ISCHEMIA: THE DEADLY DUO IN PATIENTS WITH SYMPTOMATIC PERIPHERAL ARTERY DISEASE
Male
C-reactive protein
Peripheral Arterial Disease
03 medical and health sciences
Diabetes mellitus
0302 clinical medicine
Ischemia
Peripheral arterial disease
Diabetes mellitus ; Extremities – blood supply ; Ischemia ; Inflammation ; C-reactive protein ; Mortality ; Peripheral arterial disease
Humans
Infl ammation
Aged
Aged, 80 and over
Leg
R
Stroke Volume
Middle Aged
Extremities – blood supply
3. Good health
Survival Rate
C-Reactive Protein
Medicine
Female
Diabetic Angiopathies
DOI:
10.20471/acc.2016.55.02.09
Publication Date:
2016-12-27T07:38:36Z
AUTHORS (1)
ABSTRACT
Inflammation plays an important role in the initiation and progression of peripheral artery disease (PAD). Patients with diabetes have an increased risk of developing PAD. Data regarding the prognostic implication of diabetes and inflammation on all-cause mortality in patients with symptomatic PAD and preserved left ventricular ejection fraction (LVEF >50%). The study was conducted at the Sestre milosrdnice University Hospital Center between January 2010 and January 2014 on 319 consecutive patients with symptomatic PAD and preserved LVEF (66.5% men, mean age 70±10 years, ankle brachial index 0.58±0.14). Thirty-eight (12%) patients died during median follow up period of 24 months (interquartile range, 16-34 months). On univariate analysis, C-reactive protein was significantly associated with all-cause mortality (HR 2.21, 95% CI 1.09-4.48). After multivariate regression analysis, age (HR 1.07, 95% CI 1.02-1.11), diabetes (HR 2.24, 95% CI 1.04-4.82), and critical limb ischemia (HR 2.22, 95% CI 1.03-4.80) remained the only independent predictors for all-cause mortality. Diabetes and critical limb ischemia are independently associated with an increased risk of mortality in symptomatic PAD patients with preserved LVEF.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....